ABSTRACT
Conflicts of interest involving physicians are commonplace in the US, occurring across many different specialties and subspecialties in a variety of clinical settings. In nephrology, two important scenarios in which conflicts of interest arise are dialysis facility joint venture (JV) arrangements and financial participation in End-stage Kidney Disease Seamless Care Organizations (ESCOs). Whether conflicts of interest occurring in either of these settings influence decision-making or patient care outcomes is not known due to a lack of transparent, publicly available information, and opportunities to conduct independent study. We discuss possible benefits and risks of nephrologist's financial participation in JVs and ESCOs and possible mechanisms for disclosure and reporting of such arrangements as well as risk mitigation.
Subject(s)
Conflict of Interest , Health Policy , Hospital-Physician Joint Ventures/ethics , Kidney Failure, Chronic/therapy , Nephrology/ethics , Renal Dialysis , Humans , Nephrology/economicsABSTRACT
Medical cannabis is widely available in the USA and legalisation is likely to expand. Despite the increased accessibility and use of medical cannabis, physicians have significant knowledge gaps regarding evidence of clinical benefits and potential harms. We argue that primary care providers have an ethical obligation to develop competency to provide cannabis to appropriate patients. Furthermore, specific ethical considerations should guide the recommendation of medical cannabis. In many cases, these ethical considerations are extensions of well-established principles of beneficence and nonmaleficence, which indicate that providers should recommend cannabis only for conditions that have the strongest evidence base. Additionally, the contested status of cannabis in American culture raises specific issues related to shared decision-making and patient education, as well as continuing clinical education.
Subject(s)
Medical Marijuana , Physicians , Beneficence , Ethics, Medical , Health Personnel , Humans , Primary Health CareSubject(s)
Betacoronavirus , Bioethical Issues , Coronavirus Infections , Health Care Rationing/ethics , Pandemics , Pneumonia, Viral , Resource Allocation/methods , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Health Care Rationing/methods , Health Policy , Health Workforce/statistics & numerical data , Hospital Bed Capacity/statistics & numerical data , Humans , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Resource Allocation/ethics , SARS-CoV-2 , United States/epidemiology , Ventilators, Mechanical/supply & distributionABSTRACT
A review of the evidence shows that bundled payments for surgical procedures can generate savings without adversely affecting patient outcomes. Less is known about the effect of bundled payments for chronic medical conditions, but early evidence suggests that cost and quality improvements may be small or non-existent. There is little evidence that bundles reduce access and equity, but continued monitoring is required.
Subject(s)
Episode of Care , Insurance, Health, Reimbursement/economics , Medicare/economics , Reimbursement Mechanisms/economics , Cost Savings , Health Care Costs , Health Care Reform , Humans , Models, Economic , Quality of Health Care , Surgical Procedures, Operative/economics , United StatesSubject(s)
Conflict of Interest , Health Facilities, Proprietary/ethics , Hospital-Physician Joint Ventures/ethics , Nephrologists/ethics , Renal Dialysis , Ambulatory Care Facilities/ethics , Ambulatory Care Facilities/legislation & jurisprudence , Health Facilities, Proprietary/legislation & jurisprudence , Hospital-Physician Joint Ventures/legislation & jurisprudence , Humans , Kidney Failure, Chronic/therapy , Physician Self-Referral/ethics , Physician Self-Referral/legislation & jurisprudence , United StatesSubject(s)
Health Care Costs , Income , Insurance, Health/economics , Health Expenditures , Humans , United StatesSubject(s)
Appointments and Schedules , Physicians/supply & distribution , Adult , Age Factors , Health Transition , Humans , Medicaid/statistics & numerical data , Medicine/statistics & numerical data , Middle Aged , Office Visits/statistics & numerical data , Patient Protection and Affordable Care Act/statistics & numerical data , Physicians, Primary Care/supply & distribution , Retirement/statistics & numerical data , Retirement/trends , Schools, Medical/supply & distribution , Time Factors , United States , Waiting ListsABSTRACT
Importance: As COVID-19 vaccine distribution continues, policy makers are struggling to decide which groups should be prioritized for vaccination. Objective: To assess US adults' preferences regarding COVID-19 vaccine prioritization. Design, Setting, and Participants: This survey study involved 2 independent, online surveys of US adults aged 18 years and older, 1 conducted by Gallup from September 14 to 27, 2020, and the other conducted by the COVID Collaborative from September 19 to 25, 2020. Samples were weighted to reflect sociodemographic characteristics of the US population. Exposures: Respondents were asked to prioritize groups for COVID-19 vaccine and to rank their prioritization considerations. Main Outcomes and Measures: The study assessed prioritization preferences and agreement with the National Academies of Science, Engineering, and Medicine's Preliminary Framework for Equitable Allocation of COVID-19 Vaccine. Results: A total of 4735 individuals participated, 2730 (1474 men [54.1%]; mean [SD] age, 59.2 [14.5] years) in the Gallup survey and 2005 (944 men [47.1%]; 203 participants [21.5%] aged 55-59 years) in the COVID Collaborative survey. In both the Gallup COVID-19 Panel and COVID Collaborative surveys, respondents listed health care workers (Gallup, 93.6% [95% CI, 91.2%-95.3%]; COVID Collaborative, 80.0% [95% CI, 78.0%-81.9%]) and adults of any age with serious comorbid conditions (Gallup, 78.6% [95% CI, 75.2%-81.7%]; COVID Collaborative, 72.9% [95% CI, 70.7%-74.9%]) among their 4 highest priority groups. Respondents of all political affiliations agreed with prioritizing Black, Hispanic, Native American, and other communities that have been disproportionately affected by COVID-19 (Gallup, 74.2% [95% CI, 70.6%-77.5%]; COVID Collaborative, 84.9% [95% CI, 83.1%-86.5%]), and COVID Collaborative respondents were willing to be preceded in line by teachers and childcare workers (92.5%; 95% CI, 91.2%-93.7%) and grocery workers (85.9%; 95% CI, 84.2%-87.5%). Older respondents in both surveys were significantly less likely than younger respondents to prioritize healthy adults aged 65 years and older among their 4 highest priority groups (Gallup, 23.7% vs 39.1% [χ2 = 2160.8; P < .001]; COVID Collaborative, 23.3% vs 28.8% [χ2 = 5.0198; P = .03]). COVID Collaborative respondents believed the 4 most important considerations for prioritization were preventing COVID-19 spread (78.4% [95% CI, 76.3%-80.3%]), preventing the most deaths (72.1% [95% CI, 69.9%-74.2%]), preventing long-term complications (68.9% [66.6%-71.9%]), and protecting frontline workers (63.8% [95% CI, 61.5%-66.1%]). Conclusions and Relevance: US adults broadly agreed with the National Academies of Science, Engineering, and Medicine's prioritization framework. Respondents endorsed prioritizing racial/ethnic communities that are disproportionately affected by COVID-19, and older respondents were significantly less likely than younger respondents to endorse prioritizing healthy people older than 65 years. This provides reason for caution about COVID-19 vaccine distribution plans that prioritize healthy adults older than a cutoff age without including those younger than that age with preexisting conditions, that aim solely to prevent the most deaths, or that give no priority to frontline workers or disproportionately affected communities.
Subject(s)
Attitude to Health , COVID-19 Vaccines/therapeutic use , COVID-19/prevention & control , Mass Vaccination/psychology , Public Opinion , Adolescent , Adult , Ethnicity/psychology , Female , Health Priorities , Humans , Male , Middle Aged , Minority Groups/psychology , Racial Groups/psychology , SARS-CoV-2 , Surveys and Questionnaires , Young AdultABSTRACT
The US has nearly 4.5% of the world's population but accounts for more than 40% of global drug spending. With the upcoming 2020 election, a top priority of many voters is to better control drug prices and reform the pharmaceutical market. In this Special Communication, the drug price mechanisms and government regulations used in 6 representative peer countries are evaluated: Australia, France, Germany, Norway, Switzerland, and the United Kingdom. Drug price regulation is compared with that currently used in the US. Eight key lessons from the regulations used in these countries and which elements are incorporated into the bills currently making their way through the US Congress are evaluated (2 from the US House of Representatives and 1 from the US Senate). None of these bills is as systemic or comprehensive in its drug pricing mechanisms and regulations as the schemes in the other countries.
Subject(s)
Drug Costs/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , Economic Competition/legislation & jurisprudence , Health Expenditures , Drugs, Generic , Health Policy , HumansABSTRACT
Coronavirus disease 2019 can lead to respiratory failure. Some patients require extracorporeal membrane oxygenation support. During the current pandemic, health care resources in some cities have been overwhelmed, and doctors have faced complex decisions about resource allocation. We present a case in which a pediatric hospital caring for both children and adults seeks to establish guidelines for the use of extracorporeal membrane oxygenation if there are not enough resources to treat every patient. Experts in critical care, end-of-life care, bioethics, and health policy discuss if age should guide rationing decisions.
Subject(s)
Coronavirus Infections/epidemiology , Extracorporeal Membrane Oxygenation/methods , Health Care Rationing/ethics , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Severe Acute Respiratory Syndrome/therapy , Adolescent , COVID-19 , Child , Clinical Decision-Making/ethics , Coronavirus Infections/therapy , Critical Care/economics , Critical Care/methods , Extracorporeal Membrane Oxygenation/statistics & numerical data , Female , Health Care Rationing/economics , Humans , Male , Needs Assessment , Pneumonia, Viral/therapy , United StatesSubject(s)
COVID-19 Vaccines , COVID-19/prevention & control , Health Knowledge, Attitudes, Practice , Pandemics , Patient Acceptance of Health Care , Public Opinion , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , COVID-19/virology , Child , Female , Humans , Male , Mandatory Programs , Middle Aged , SARS-CoV-2 , United States/epidemiology , Young AdultABSTRACT
PURPOSE: To review radiographic findings of patients with probable severe acute respiratory syndrome (SARS) who were seen at a University of Toronto (Ontario, Canada) teaching hospital. MATERIALS AND METHODS: Findings were reviewed for 40 patients who fulfilled the World Health Organization criteria for probable SARS. A template was designed for the analysis of each serial radiograph to observe patterns and distribution of disease, interval changes, and complications. The majority of radiographs were anteroposterior views. A clinical database of these patients was also collected for clinical-radiologic comparison. RESULTS: The mean age of the patients (18 male, 22 female) was 42.7 years. Patients had a normal chest radiograph and focal, multifocal, and/or bilateral consolidation. The pattern of consolidation tended to be peripheral and poorly marginated and involved middle and lower lung zones. The serial sequence fell into two major subgroups, which correlated closely with clinical outcome. Consolidation in one group cleared within a matter of days, while the second group went on to develop rapid and extensive bilateral pneumonia, with a prolonged hospital stay. Subsegmental atelectasis and pleural complications were rarely observed. CONCLUSION: SARS pneumonia can manifest as focal peripheral consolidation that clears relatively quickly and does not cause secondary complications or that progresses to bilateral consolidation and a more protracted clinical course.